Skip to main content
TIBET AIM PHARM. INC. logo

TIBET AIM PHARM. INC. — Investor Relations & Filings

Ticker · 002826 ISIN · CNE100002C39 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,085 across all filing types
Latest filing 2020-11-12 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 002826

About TIBET AIM PHARM. INC.

https://www.emyy.cn

Tibet Aim Pharm. Inc. is a pharmaceutical enterprise focused on the research, development, production, and distribution of medicinal products. The company integrates traditional Tibetan medicine with modern pharmaceutical manufacturing processes to develop a diverse portfolio of treatments. Its core product range typically includes cardiovascular medications, digestive system therapies, and specialized herbal formulations derived from high-altitude botanical sources. Tibet Aim Pharm. Inc. emphasizes the modernization of traditional formulas through rigorous clinical testing and standardized production techniques. The company serves healthcare providers and patients by providing therapeutic solutions that bridge ancient medical knowledge with contemporary scientific standards.

Recent filings

Filing Released Lang Actions
关于股东减持计划时间过半的进展公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the progress of a shareholder's share reduction plan, detailing the number of shares reduced, the methods of reduction, and the impact on shareholding percentages. It references compliance with securities laws and regulations related to shareholder share reductions. There is no financial report, earnings data, or management discussion. The content focuses on shareholding changes by a significant shareholder and the regulatory compliance of this activity. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2020-11-12 Chinese
2019年限制性股票激励计划（草案修订稿）摘要
Remuneration Information Classification · 95% confidence The document is a detailed plan regarding a 2019 restricted stock incentive plan for a company, including legal compliance, stock allocation, eligibility, vesting conditions, performance targets, and governance related to the stock incentive program. It is not a financial report, earnings release, or regulatory announcement but a comprehensive management-level document about stock-based compensation. This fits the category of Remuneration Information (DEF 14A), which covers executive and director compensation plans and related disclosures. The document is lengthy and substantive, not a brief announcement or certification, so it is not RPA or RNS. Therefore, the best classification is DEF 14A with high confidence.
2020-11-02 Chinese
2019年限制性股票激励计划实施考核管理办法
Governance Information Classification · 95% confidence The document is titled as an implementation and assessment management method for a 2019 restricted stock incentive plan of a company. It details the governance structure, assessment principles, scope, performance evaluation indicators, assessment periods, procedures, and feedback mechanisms related to the stock incentive plan. There is no indication that this is a financial report, audit report, earnings release, or any other financial filing. Instead, it is a governance-related document focusing on the company's internal rules and procedures for stock incentive plan assessment and management. This fits the definition of Governance Information (CGR). The document length is 4327 characters, which is not extremely short, and it contains substantive content rather than just an announcement or certification. Therefore, the best classification is CGR with high confidence.
2020-11-02 Chinese
2019年限制性股票激励计划（草案修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed plan titled "2019年限制性股票激励计划（草案修订稿）" which translates to "2019 Restricted Stock Incentive Plan (Draft Revision)" for 西藏易明西雅医药科技股份有限公司. It extensively discusses the terms, conditions, management, allocation, and legal compliance of a stock-based incentive plan for company executives and key employees. The content includes legal references, stock quantities, grant prices, vesting conditions, performance targets, and governance related to the stock incentive plan. This is a comprehensive disclosure about a capital/financing activity related to the issuance of restricted stock as an incentive. It is not an annual or interim financial report, audit report, earnings release, or management discussion. It is not a voting result, board change, or legal proceeding. It is not a proxy or AGM material. The document is a formal announcement and detailed description of a stock incentive plan, which falls under Capital/Financing Update (CAP) as it relates to changes in capital structure and financing instruments through stock issuance to employees as incentives.
2020-11-02 Chinese
北京国枫律师事务所关于公司修订2019年限制性股票激励计划公司层面业绩考核指标相关事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the revision of a 2019 restricted stock incentive plan for a company. It discusses legal compliance, approval procedures, and the background and content of the revision to the stock incentive plan's performance assessment indicators. The document is not a financial report, earnings release, or management discussion, but a legal opinion related to corporate governance and stock incentive plans. It does not contain financial statements or earnings data, nor is it a regulatory announcement or a proxy solicitation. The document fits best into the category of Regulatory Filings (RNS) as it is a legal opinion letter related to corporate governance and compliance matters, which do not fit into more specific categories.
2020-11-02 Chinese
关于取消2020年第二次临时股东大会提案并增加临时提案暨股东大会补充通知的公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is an announcement regarding the cancellation and addition of proposals for the 2020 second extraordinary general meeting of shareholders of a company. It details the meeting logistics, voting procedures, and agenda items, specifically about revising a 2019 restricted stock incentive plan. It includes information on meeting time, place, voting methods, and proxy forms. There is no financial data or report content, but rather a notice about the shareholder meeting and its agenda. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is about the meeting notice and agenda changes rather than solicitation materials or voting results, it is best classified as a Proxy Solicitation & Information Statement (PSI). The document length is about 4932 characters, which is consistent with a detailed meeting notice and proxy information.
2020-11-02 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.